CBD-THC Mixture Helped Brain Immune Cells Clear Alzheimer's Plaques in Mice

A 99:1 CBD:THC botanical mixture enhanced microglial clearance of amyloid plaques in Alzheimer's mice, but also increased anxiety and depression-like behaviors.

Ruiz de Martín Esteban, Samuel et al.·Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2026·Moderate EvidenceAnimal StudyAnimal Study
RTHC-08591Animal StudyModerate Evidence2026RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Animal Study
Evidence
Moderate Evidence
Sample
Not reported

What This Study Found

Chronic treatment (28 days) with CBD:THC (99:1) at 50 mg/kg twice daily in 5xFAD Alzheimer's mice enhanced microglial phagocytic activity and reduced amyloid peptide accumulation in neuritic plaques. However, the treatment also reduced locomotion, increased anxiety-like and depression-like behaviors, and had no effect on memory or motor coordination.

Key Numbers

50 mg/kg twice daily for 28 days. CBD:THC ratio 99:1. Enhanced microglial phagocytic activity by flow cytometry. Reduced amyloid accumulation by multiphoton microscopy. Increased anxiety and depression-like behaviors. No memory or motor coordination effects.

How They Did This

Male 5xFAD Alzheimer's mice treated with CBD:THC (99:1) 50 mg/kg subcutaneously twice daily for 28 days. Behavioral battery, protein expression analysis, flow cytometry for phagocytosis, and in vivo multiphoton microscopy for plaque imaging.

Why This Research Matters

This is one of the first studies to show cannabinoids can enhance the brain's own plaque-clearing mechanisms in a living Alzheimer's model. However, the behavioral side effects present a clear challenge for translation to human treatment.

The Bigger Picture

The dual finding of enhanced plaque clearance alongside worsened behavior epitomizes the challenge of cannabinoid therapeutics in neurodegeneration. The immune benefits may be achievable at lower doses that avoid behavioral side effects, but this needs testing.

What This Study Doesn't Tell Us

Only male mice studied. High subcutaneous dose (50 mg/kg BID) far exceeds typical human dosing. The 5xFAD model represents aggressive amyloid pathology, not all aspects of human Alzheimer's. 28-day treatment may be too short.

Questions This Raises

  • ?Could lower doses maintain the plaque-clearing benefits without the behavioral side effects?
  • ?Would oral administration produce the same immune effects?

Trust & Context

Key Stat:
Enhanced plaque clearance but increased anxiety/depression
Evidence Grade:
Well-designed preclinical study using advanced imaging (multiphoton microscopy), but only male mice and high doses limit translational relevance.
Study Age:
2026 study.
Original Title:
Treatment with a botanical mixture of cannabidiol:Δ9-tetrahydrocannabinol enhances microglial phagocytosis and shapes amyloid plaques in a mouse model of Alzheimer's disease.
Published In:
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 194, 118902 (2026)
Database ID:
RTHC-08591

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / Observational
Case Report / Animal StudyOne case or non-human subjects
This study

Tests effects in animals (usually mice or rats), not humans.

What do these levels mean? →

Frequently Asked Questions

Can CBD help clear Alzheimer's plaques?

In this mouse study, a CBD-dominant mixture enhanced the brain's immune cells (microglia) to better clear amyloid plaques. However, the same treatment worsened anxiety and depression behaviors.

Why is the CBD:THC ratio 99:1?

The formulation is CBD-dominant with a trace of THC. This reflects the growing interest in botanical mixtures that may have different effects than pure CBD or pure THC alone.

Read More on RethinkTHC

Cite This Study

RTHC-08591·https://rethinkthc.com/research/RTHC-08591

APA

Ruiz de Martín Esteban, Samuel; Grande, M Teresa; Martínez-Relimpio, Ana M; Herráez-Aguilar, Diego; Mostany, Ricardo; Hillard, Cecilia J; Hind, William H; Romero, Julián. (2026). Treatment with a botanical mixture of cannabidiol:Δ9-tetrahydrocannabinol enhances microglial phagocytosis and shapes amyloid plaques in a mouse model of Alzheimer's disease.. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 194, 118902. https://doi.org/10.1016/j.biopha.2025.118902

MLA

Ruiz de Martín Esteban, Samuel, et al. "Treatment with a botanical mixture of cannabidiol:Δ9-tetrahydrocannabinol enhances microglial phagocytosis and shapes amyloid plaques in a mouse model of Alzheimer's disease.." Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2026. https://doi.org/10.1016/j.biopha.2025.118902

RethinkTHC

RethinkTHC Research Database. "Treatment with a botanical mixture of cannabidiol:Δ9-tetrahy..." RTHC-08591. Retrieved from https://rethinkthc.com/research/ruiz-2026-treatment-with-a-botanical

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.